Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 159

Related Citations for PubMed (Select 10502819)

1.

A universal influenza A vaccine based on the extracellular domain of the M2 protein.

Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W.

Nat Med. 1999 Oct;5(10):1157-63.

PMID:
10502819
2.
3.

Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant.

Sui Z, Chen Q, Wu R, Zhang H, Zheng M, Wang H, Chen Z.

Arch Virol. 2010 Apr;155(4):535-44. doi: 10.1007/s00705-010-0621-4. Epub 2010 Feb 27.

PMID:
20195654
4.
5.

Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies.

De Filette M, Martens W, Smet A, Schotsaert M, Birkett A, Londoño-Arcila P, Fiers W, Saelens X.

Vaccine. 2008 Dec 2;26(51):6503-7. doi: 10.1016/j.vaccine.2008.09.038.

PMID:
18835315
7.

Universal influenza A vaccine: optimization of M2-based constructs.

De Filette M, Min Jou W, Birkett A, Lyons K, Schultz B, Tonkyro A, Resch S, Fiers W.

Virology. 2005 Jun 20;337(1):149-61.

8.

A "universal" human influenza A vaccine.

Fiers W, De Filette M, Birkett A, Neirynck S, Min Jou W.

Virus Res. 2004 Jul;103(1-2):173-6. Review.

PMID:
15163506
9.

Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin.

Huleatt JW, Nakaar V, Desai P, Huang Y, Hewitt D, Jacobs A, Tang J, McDonald W, Song L, Evans RK, Umlauf S, Tussey L, Powell TJ.

Vaccine. 2008 Jan 10;26(2):201-14. Epub 2007 Nov 20.

PMID:
18063235
10.

Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein.

Slepushkin VA, Katz JM, Black RA, Gamble WC, Rota PA, Cox NJ.

Vaccine. 1995;13(15):1399-402.

PMID:
8578816
11.

In contrast to conventional inactivated influenza vaccines, 4xM2e.HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran.

Ebrahimi SM, Dabaghian M, Tebianian M, Jazi MH.

Virology. 2012 Aug 15;430(1):63-72. doi: 10.1016/j.virol.2012.04.015. Epub 2012 May 16.

12.
13.

Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant.

Sui Z, Chen Q, Fang F, Zheng M, Chen Z.

Vaccine. 2010 Nov 10;28(48):7690-8. doi: 10.1016/j.vaccine.2010.09.019. Epub 2010 Sep 24.

PMID:
20870054
14.
15.

Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys.

Fan J, Liang X, Horton MS, Perry HC, Citron MP, Heidecker GJ, Fu TM, Joyce J, Przysiecki CT, Keller PM, Garsky VM, Ionescu R, Rippeon Y, Shi L, Chastain MA, Condra JH, Davies ME, Liao J, Emini EA, Shiver JW.

Vaccine. 2004 Aug 13;22(23-24):2993-3003.

PMID:
15297047
16.

Modified M2 proteins produce heterotypic immunity against influenza A virus.

Frace AM, Klimov AI, Rowe T, Black RA, Katz JM.

Vaccine. 1999 May 4;17(18):2237-44.

PMID:
10403591
17.

[Construction, expression and immunogenicity analysis of a fusion protein containing M2e of influenza A virus fused to a modified Pseudomonas aeruginosa exotoxin A].

Xu Y, Yao LH, Chen AJ, Guo JQ, Liu XY, Bo H, Liu LQ, Shu YL, Zhang ZQ.

Bing Du Xue Bao. 2010 May;26(3):189-94. Chinese.

PMID:
20572339
19.

Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1.

Tompkins SM, Zhao ZS, Lo CY, Misplon JA, Liu T, Ye Z, Hogan RJ, Wu Z, Benton KA, Tumpey TM, Epstein SL.

Emerg Infect Dis. 2007 Mar;13(3):426-35.

20.

Improved design and intranasal delivery of an M2e-based human influenza A vaccine.

De Filette M, Fiers W, Martens W, Birkett A, Ramne A, Löwenadler B, Lycke N, Jou WM, Saelens X.

Vaccine. 2006 Nov 10;24(44-46):6597-601. Epub 2006 Jun 12.

PMID:
16814430
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk